4 Minutes
A daily pill appears to change the odds for a specific group of people with type 2 diabetes: those who have already experienced heart failure. New reanalysis of a large, double-blind trial suggests that oral semaglutide—an oral GLP-1 receptor agonist sold in some formulations as Ozempic or Wegovy—was associated with fewer heart-related hospitalizations and deaths among participants with a prior history of heart failure.
Study details and headline results
The dataset comes from a global trial funded by Novo Nordisk that enrolled 9,650 people across 33 countries between 2019 and 2021. Participants were followed for nearly four years on average. Researchers performed a secondary, prespecified analysis that separated patients by whether they had a documented history of heart failure at baseline.
Among those with prior heart failure, patients taking a daily oral dose of semaglutide experienced about 22% fewer major cardiovascular events—hospital admissions and deaths tied to heart problems—compared with those who received placebo. For people without pre-existing heart disease, the analysis did not detect a measurable cardiovascular benefit.
"These data support the potential benefit of oral semaglutide in reducing heart failure events in people with type 2 diabetes and heart conditions," write Rodica Pop-Busui and colleagues from Oregon Health & Science University in their paper. They also caution that the analysis inherits limits typical of a secondary study, including smaller numbers in some subgroups and reduced statistical power.
Context, mechanisms and safety signals
The finding echoes earlier trials that reported roughly a 15–20% reduction in major cardiovascular events—strokes and heart attacks included—over about three years for certain patients on GLP-1 therapies. Intriguingly, several analyses suggest those cardiovascular gains can appear independently of weight loss, implying effects beyond simply shedding kilos.
That is hopeful. But it is also puzzling. Why would semaglutide help people who already have heart failure but not those without prior heart disease? The short answer: we do not yet know. Researchers have called for mechanistic studies to explain how GLP-1 receptor agonists influence cardiac biology in humans.
Worrying signals from preclinical models add complexity. A 2024 mouse study reported reductions in cardiomyocyte size and evidence of skeletal muscle loss alongside the intended fat loss and improved glucose control. The cardiomyocyte image captioned in that paper reads: "The cardiomyocyte area of mice without (left) and with semaglutide treatment (right). (Martens et al., The Lancet, 2024)". Animal findings do not translate directly to people, but they do prompt caution and closer monitoring.
Side effects in humans—nausea, vomiting and gastrointestinal upset—are common and well documented. Longer-term effects, particularly on muscle and cardiac structure, remain under investigation.
Type 2 diabetes affects roughly half a billion people worldwide, and heart failure ranks among its most frequent and serious complications. For patients who carry both diagnoses, the balance of benefit and risk may tilt in favor of semaglutide when the drug is prescribed and followed by clinicians experienced in diabetes and cardiovascular care. Still, alternatives such as bariatric surgery often deliver superior glycemic control in eligible patients, and widespread off-label use of GLP-1 drugs for cardiovascular protection remains premature without clearer mechanistic evidence and longer follow-up.
Clinicians and patients must weigh potential heart benefits against uncertain long-term risks, and researchers must now aim squarely at why these benefits appear in some groups but not others.
Source: sciencealert
Leave a Comment